Syngene International has tied up with Zumutor Biologics, for Biotherapeutic antibody services.

It has entered into a non-exclusive partnering agreement with Zumutor Biologics, to access Zumutor’s proprietary naive human phage/yeast display library. As per the terms of agreement, Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partners.

Further, Manoj Nerurkar, Chief Operating Officer of Syngene International said, “Syngene has been a pioneer in discovery research and we see Discovery Biology as one of our growth drivers. This partnership will expand our existing portfolio of therapeutic antibody discovery platforms for our clients.”

Read EquityPandit’s Technical Analysis of Indian Stock Market